Valproic acid use in fertile women with genetic generalized epilepsies.

David SteinbartVerena GausAlexander B KowskiMartin Holtkamp

Published in: Acta neurologica Scandinavica (2021)

Despite warnings with respect to teratogenicity and impaired cognitive development with VPA, from 2015 to 2020, almost every fourth women of fertile age with GGE received this compound. Inevitably lower VPA doses in these women seem sufficient for favorable seizure freedom rates.

Keyphrases

polycystic ovary syndrome
pregnancy outcomes
cervical cancer screening
pregnant women
insulin resistance
copy number
gene expression
dna methylation
adipose tissue